Therapieergebnisse und toxische Nebenwirkungen der Kombination Cytostasan, Adriamycin und Vincristin als „Second line“-Therapie beim metastasierten Mammakarzinom
Therapieergebnisse und toxische Nebenwirkungen der Kombination Cytostasan, Adriamycin und Vincristin als „Second line“-Therapie beim metastasierten Mammakarzinom
复制标题
Cytostasan、阿霉素和长春新碱组合作为“第二线”的治疗和毒性 Nebenwirkungen - Therapie beim metastasierten Mammakarzinom
DOI：
10.1055/s-2007-1026163
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
K. Ebeling
中科院分区：
文献类型：
--
作者：
B. Brockmann;E. Geschke;U. Schmidt;K. Ebeling
Remission rates of 30-50% can be obtained using different cytostatic combinations in second line therapy of metastatic breast cancer. The combination of adriamycin and vincristin with cytostasan revealed a remission rate of 50% in 62 CMF-pretreated patients. Considerable toxic side effects led to a dose reduction of cytostasan and adriamycine in 43 patients without clinical efficacy loss. The long remission periods of the total responders (8-23 months) were remarkable. Both, 3 patients with bone +/- soft tissue metastasis and 4 patients with visceral metastasis benefited from a clinical total remission. The remission rates indicated no significant differences between the group of patients with soft tissue +/- bone metastasis (47.3%) and that with a predominantly visceral metastasis (50%). The CyAV-combination with a low dosage provides an effective therapeutical scheme with acceptable side effects for CMF-pretreated patients with breast cancer.
